GCM
IDYA icon

Gladius Capital Management’s IDEAYA Biosciences IDYA Stock Holding History

Gladius Capital Management’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,686
Closed -$55K – 392
2022
Q3 		$55K Buy
+3,686
New +$47.9K ﹤0.01% 207

Other funds holding IDYA

LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Gladius Capital Management's IDYA Position: Q4 2022 in Review

Gladius Capital Management sold out of IDEAYA Biosciences (IDYA) in Q4 2022, closing a stake of 3,686 shares — an estimated $55K sold.

Gladius Capital Management first reported a position in IDYA in Q3 2022 and held it in 1 quarter. The position peaked at $55K in Q3 2022. 117 funds tracked by Wall St. Rank hold IDYA as of Q4 2022.

  • Gladius Capital Management reported no remaining IDEAYA Biosciences position as of Q4 2022 after selling out during the quarter.
  • Gladius Capital Management sold 3,686 IDEAYA Biosciences shares in Q4 2022, an estimated $55K.
  • Gladius Capital Management first reported a position in IDEAYA Biosciences in Q3 2022 and held it in 1 quarter.
  • Gladius Capital Management's IDEAYA Biosciences position peaked at $55K in Q3 2022.
  • 117 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q4 2022.

Based on Gladius Capital Management's 13F filing for Q4 2022, filed 2 Feb 2023.